Drug Trial Radar · NCT05976802
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 2029
Primary completion
Jun 2030
Study completion Jan 2031
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy (as measured by induction of remission) of two dose levels (low and high) per age group (5 to \<12 and 12 to ≤17 years) of budesonide rectal foam as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in pediatric subjects with active, mild to moderate distal ulcerative colitis (UC).
Conditions
- Ulcerative Colitis
Interventions
High dose budesonide rectal foamDrug
Twice a day for 2 weeks, then once a day for 4 weeks
Low dose budesonide rectal foamDrug
Twice a day for 2 weeks, then once a day for 4 weeks
Matching placebo rectal foamDrug
Twice a day for 2 weeks, then once a day for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with clinical remissionTime frame: Day 42
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.